Morgan Stanley Reaffirms Equal Weight Rating for Ascendis Pharma A/S (NASDAQ:ASND)

Morgan Stanley reiterated their equal weight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a report issued on Monday, Benzinga reports. They currently have a $116.00 price target on the biotechnology company’s stock.

A number of other equities research analysts have also recently weighed in on the stock. Cantor Fitzgerald restated an overweight rating and issued a $173.00 price objective on shares of Ascendis Pharma A/S in a report on Thursday, April 18th. StockNews.com upgraded shares of Ascendis Pharma A/S from a sell rating to a hold rating in a report on Monday, December 25th. JPMorgan Chase & Co. upped their price objective on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an overweight rating in a report on Tuesday, April 2nd. Citigroup upped their price objective on shares of Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a buy rating in a report on Thursday, February 8th. Finally, Wedbush upped their target price on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an outperform rating in a research note on Thursday, February 8th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of Moderate Buy and a consensus target price of $173.25.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ ASND opened at $142.10 on Monday. The stock has a market capitalization of $8.27 billion, a P/E ratio of -15.36 and a beta of 0.50. Ascendis Pharma A/S has a 1 year low of $66.03 and a 1 year high of $161.00. The company’s 50-day moving average is $149.12 and its 200 day moving average is $125.10.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.15) by $0.49. The business had revenue of $148.62 million for the quarter, compared to analysts’ expectations of $97.02 million. Ascendis Pharma A/S had a negative net margin of 180.61% and a negative return on equity of 16,574.15%. Research analysts anticipate that Ascendis Pharma A/S will post -4.15 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC bought a new position in Ascendis Pharma A/S during the fourth quarter valued at approximately $25,000. Private Ocean LLC bought a new position in Ascendis Pharma A/S during the first quarter valued at approximately $36,000. Quadrant Capital Group LLC lifted its position in Ascendis Pharma A/S by 90.4% during the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 151 shares during the period. EverSource Wealth Advisors LLC lifted its position in Ascendis Pharma A/S by 37.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 91 shares during the period. Finally, Signaturefd LLC lifted its position in Ascendis Pharma A/S by 31.9% during the third quarter. Signaturefd LLC now owns 798 shares of the biotechnology company’s stock valued at $75,000 after purchasing an additional 193 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.